Rankings
▼
Calendar
TNGX Q4 2024 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TNGX
Tango Therapeutics, Inc.
$2B
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$4M
-24.2% YoY
Gross Profit
$4M
100.0% margin
Operating Income
-$41M
-993.7% margin
Net Income
-$38M
-915.0% margin
EPS (Diluted)
$-0.34
QoQ Revenue Growth
-64.5%
Cash Flow
Operating Cash Flow
-$37M
Free Cash Flow
-$37M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$316M
Total Liabilities
$117M
Stockholders' Equity
$200M
Cash & Equivalents
$70M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$4M
$5M
-24.2%
Gross Profit
$4M
$5M
-24.2%
Operating Income
-$41M
-$35M
-16.8%
Net Income
-$38M
-$31M
-22.5%
Revenue Segments
Collaboration Revenue
$18M
100%
← FY 2024
All Quarters
Q1 2025 →